Benefits
Generalized anxiety disorder vs medazepam (pivotal)
In a 2008 Russian-language trial, 62 people already diagnosed with generalized anxiety disorder and neurasthenia received either selank (30 people) or the benzodiazepine medazepam (32 people). The paper reports that the anxiolytic effects of the two drugs were similar, and that selank also showed antiasthenic and psychostimulant effects. Important limits: this is a drug versus drug comparison in psychiatric patients with no placebo group, so it cannot show either drug beat placebo; the group is small; the abstract does not state the dose or the route; the route marketed in Russia is a nasal spray, not something swallowed; and it is a Russian-language original from one national research network with limited independent replication. It describes what happened in people being treated for a diagnosed anxiety disorder, not what selank does for a healthy person.
No cited comparison with phenazepam
None of the three references listed on this page is a comparison against phenazepam, so nothing here supports a claim that selank matches that drug or has a better side effect profile. The only human comparison cited is the 2008 trial against medazepam described above, and it did not measure quality of life against phenazepam. Claims of superior tolerability are not backed by any study cited here.
No cited evidence on speed of response
No reference cited on this page reports a rapid responder analysis. The response rates, symptom scores, timelines and EEG findings previously listed here cannot be traced to any of the three studies cited. Nothing in the cited evidence shows how quickly, or whether, symptoms change on any particular schedule.
GABA-A allosteric modulation
The cited support for this is a laboratory review with in vitro radioligand binding work, which found that selank behaves as a positive allosteric modulator at the GABA site rather than a direct agonist. The gene expression work described here was done in rodent brain tissue, not in people. This is test tube and animal level mechanism only. It does not show that selank changes anxiety in a person, and it is not evidence that selank avoids dependence or withdrawal, because no cited study measured dependence or withdrawal.
Enkephalin stabilization (anxiolytic mechanism)
Laboratory work suggests selank slows the enzymes that break down enkephalins, the body's own calming opioid peptides, which would let them last longer. The cited support is a laboratory review plus a Russian-language study in mice that were given selank by injection into the abdomen, not by mouth. This is a proposed mechanism, not a measured benefit in people.
No cited evidence for anti-inflammatory effects
No reference cited on this page measured inflammation, IL-6, chronic fatigue or fibromyalgia symptoms, so there is nothing here to support an anti-inflammatory effect or any use in those conditions. Informal clinical impressions are not trial results.
Mechanism of action
Allosteric GABA-A receptor modulation (not direct agonist)
Selank functions as allosteric GABA-A modulator — alters receptor activity through non-active site binding. Distinguishes from benzodiazepines (which are direct GABA-A modulators at the benzodiazepine binding site). It is often suggested that this could mean less sedation, tolerance or withdrawal than benzodiazepines, but none of the studies cited here measured dependence, tolerance or withdrawal, so this is an untested idea rather than a demonstrated advantage.
Enkephalin-degrading enzyme inhibition
Inhibits enzymes that break down enkephalin endogenous opioid peptides. Extending enkephalin activity is a proposed way selank might calm anxiety, but this comes from laboratory and injected-animal work and has not been shown to steady mood in people in any study cited here. Mechanism distinct from exogenous opioid agonists — modulates endogenous tone.
Serotonin metabolism modulation
Animal work suggests selank affects serotonin handling in the brain. None of the three references cited on this page tested this, and it has not been shown in people.
Tuftsin-derived immunomodulation
Selank contains tuftsin tetrapeptide N-terminus (Thr-Lys-Pro-Arg) — endogenous immunomodulatory peptide. It may share some of tuftsin's immune signalling properties in the laboratory. No study cited here measured immune or inflammatory outcomes in people, so there are no clinical anti-inflammatory effects to explain.
BDNF and gene expression effects
Modulates expression of multiple genes involved in BDNF pathway, glucocorticoid receptors, and stress response. This comes from rodent gene expression work. None of the references cited here measured it, and gene changes in rodents do not establish a lasting anti-anxiety effect in people.
Intranasal BBB penetration
Intranasal administration provides direct CNS access via olfactory and trigeminal nerves — bypassing first-pass hepatic metabolism. This also means the opposite for anything swallowed: peptides like selank are broken down by digestion, and there is no cited evidence that an oral capsule of selank does anything at all. The onset times quoted online do not come from any study cited here.
Clinical trials
Russian-language clinical trial (Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB 2008, Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38-48).
62 patients with generalized anxiety disorder (GAD) and neurasthenia. Selank (n=30) vs medazepam (n=32, benzodiazepine). Hamilton, Zung, CGI psychometric scales. Enkephalin activity in blood serum measured.
The paper reports that the anxiolytic effects of the two drugs were similar, and that selank also showed antiasthenic and psychostimulant effects. There was no placebo group, so both arms received an active drug and the trial cannot show that either worked better than placebo. The abstract does not state the dose or the route used. Clinical-biological study: GAD/neurasthenia patients had decreased τ½ leu-enkephalin correlated with disease duration, anxiety severity, asthenia, autonomic disorders. Selank treatment increased this parameter with stronger positive correlations with anxiety level. Russian-language literature limits Western methodological scrutiny.
Mechanistic study (Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB 2001, Bull Exp Biol Med 131(4):315-317, doi:10.1023/a:1017979514274).
Biochemical study of selank effects on enkephalin-degrading enzymes in serum/tissue.
Selank inhibits enkephalin-degrading enzymes — extending duration of endogenous opioid anxiolytic peptides. This is a laboratory experiment, not a clinical trial. No patients were treated and no symptoms were measured, so it is a proposed explanation for how selank might work rather than evidence that it works.
Behavioral and gene expression study (Kasian A, Kolomin T, Yatskou M, Myasoedov N, Slominsky P, Behav Neurol 2017:5091027, doi:10.1155/2017/5091027).
Rats in unpredictable chronic mild stress paradigm receiving selank ± diazepam. Frontal cortex transcriptome (45 GABAergic genes) analyzed within 1 hour post-administration.
Selank altered expression of 45 GABAergic genes within 1 hour. Pattern showed positive correlation with GABA itself — indicating selank functions as allosteric GABA-A modulator rather than direct agonist. Selank increased the effect of diazepam in a rodent stress model, which is a caution about combining it with sedative medicines rather than a selling point. This is an animal study in rats, not a clinical trial, and nothing in it measured dependence, tolerance or withdrawal, so it cannot support a safety advantage over benzodiazepines.